PMGC Holdings Inc. (ELAB) 10-Year Financial Performance & Capital Metrics

ELAB • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutPMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.Show more

Revenue $2M +44.1%
EBITDA -$2M +52.4%
Net Income -$6M -45.2%
EPS (Diluted) -274.68 +86.0%
Gross Margin 72.84% +9.9%
EBITDA Margin -72.28% +67.0%
Operating Margin -75.65% +65.5%
Net Margin -253.14% -0.8%
ROE -119.12% +31.3%
ROIC -82.69% +85.8%
Debt/Equity -
Interest Coverage -2.54 +98.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 96.7% through buybacks
✓Trading at only 0.0x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y1339.59%

TTM-179.8%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-21.78%

EPS CAGR

10Y-

5Y-

3Y-

TTM89.91%

ROCE

10Y Avg-187.48%

5Y Avg-187.48%

3Y Avg-127.41%

Latest-33.67%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.77B	5.77	59.36	43.5%	9.32%		1.85%
CORTCorcept Therapeutics Incorporated	3.93B	37.36	30.37	39.94%	14.19%	16.65%	4.98%	0.01
GUTSFractyl Health, Inc. Common Stock	306.74M	2.00	-1.23	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	428.81M	1.18	-1.87	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	232.75M	2.51	-2.56			-52.45%		0.01
BIOABioAge Labs, Inc.	640.01M	17.85	-2.69		-12.81%	-27.32%		0.03
MISTMilestone Pharmaceuticals Inc.	166.93M	1.96	-2.93	-100%		-282.97%		4.17
ALTAltimmune, Inc.	422.59M	4.05	-3.02	-95.31%	-4195.75%	-45.21%		0.01

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	827	766.28K	1.71M	2.47M
Revenue Growth %	-	-	925.57%	1.23%	0.44%
Cost of Goods Sold+	0	2.85K	318.97K	578.01K	670.2K
COGS % of Revenue	-	3.44%	0.42%	0.34%	0.27%
Gross Profit+	0	-2.02K	447.31K	1.13M	1.8M
Gross Margin %	-	-2.44%	0.58%	0.66%	0.73%
Gross Profit Growth %	-	-	222.66%	1.54%	0.58%
Operating Expenses+	222.91K	783.04K	2.24M	4.89M	3.66M
OpEx % of Revenue	-	946.85%	2.92%	2.86%	1.48%
Selling, General & Admin	102.99K	633.96K	1.73M	4.03M	855.76K
SG&A % of Revenue	-	766.58%	2.26%	2.35%	0.35%
Research & Development	118.86K	123.63K	228.75K	426.24K	104.65K
R&D % of Revenue	-	149.49%	0.3%	0.25%	0.04%
Other Operating Expenses	0	25.45K	277.48K	440.45K	2.7M
Operating Income+	-221.84K	-785.06K	-1.79M	-3.76M	-1.87M
Operating Margin %	-	-949.29%	-2.33%	-2.2%	-0.76%
Operating Income Growth %	-	-2.54%	-1.28%	-1.1%	0.5%
EBITDA+	0	-782.3K	-1.78M	-3.75M	-1.78M
EBITDA Margin %	-	-945.95%	-2.33%	-2.19%	-0.72%
EBITDA Growth %	-	-	-1.28%	-1.1%	0.52%
D&A (Non-Cash Add-back)	221.84K	2.76K	6.51K	11.65K	83.1K
EBIT	-221.84K	-784.74K	-1.8M	-4.28M	-3.28M
Net Interest Income+	0	0	5.07K	-13.96K	-722.31K
Interest Income	0	0	7.7K	5.56K	12.89K
Interest Expense	0	0	2.63K	19.52K	735.2K
Other Income/Expense	-1.07K	321	-11.98K	-541.44K	-2.15M
Pretax Income+	-222.91K	-784.74K	-1.8M	-4.3M	-4.02M
Pretax Margin %	-	-948.9%	-2.35%	-2.51%	-1.63%
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.55%
Net Income+	-222.91K	-784.74K	-1.8M	-4.3M	-6.25M
Net Margin %	-	-948.9%	-2.35%	-2.51%	-2.53%
Net Income Growth %	-	-2.52%	-1.29%	-1.39%	-0.45%
Net Income (Continuing)	-222.91K	-784.74K	-1.8M	-4.3M	-4.02M
Discontinued Operations	0	0	0	0	-2.23M
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.08	-0.29	-0.67	-1961.37	-274.68
EPS Growth %	-	-2.51%	-1.29%	-2948.42%	0.86%
EPS (Basic)	-0.08	-0.29	-0.67	-1961.37	-274.68
Diluted Shares Outstanding	2.7M	2.7M	2.72M	682.91K	22.74K
Basic Shares Outstanding	2.7M	2.7M	2.72M	2.19K	22.74K
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.02K	636.52K	1.55M	4.92M	6.05M
Cash & Short-Term Investments	13.35K	411.86K	1.15M	3.33M	3.98M
Cash Only	13.35K	411.86K	1.15M	3.33M	3.98M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	1.71K	12.85K	36.16K	5.28K
Days Sales Outstanding	-	754.72	6.12	7.71	0.78
Inventory	0	160.82K	230.15K	495.67K	1.04K
Days Inventory Outstanding	-	20.63K	263.36	313	0.57
Other Current Assets	3.67K	0	0	0	1.19M
Total Non-Current Assets+	0	29.73K	340.86K	270.47K	2.94M
Property, Plant & Equipment	0	29.73K	330.09K	259.7K	1.09K
Fixed Asset Turnover	-	0.03x	2.32x	6.59x	2269.82x
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	2.8M
Long-Term Investments	0	0	0	0	139.08K
Other Non-Current Assets	0	0	10.77K	10.77K	0
Total Assets+	17.02K	666.25K	1.89M	5.19M	8.99M
Asset Turnover	-	0.00x	0.40x	0.33x	0.27x
Asset Growth %	-	38.14%	1.84%	1.74%	0.73%
Total Current Liabilities+	40.61K	215.62K	588.27K	1.3M	1.8M
Accounts Payable	154	98.17K	210.84K	596.15K	481K
Days Payables Outstanding	-	12.6K	241.27	376.45	261.96
Short-Term Debt	24K	0	0	0	0
Deferred Revenue (Current)	0	0	10.17K	36.69K	0
Other Current Liabilities	16.46K	0	68.45K	369.16K	548.92K
Current Ratio	0.42x	2.95x	2.64x	3.79x	3.36x
Quick Ratio	0.42x	2.21x	2.25x	3.41x	3.36x
Cash Conversion Cycle	-	8.79K	28.21	-55.74	-260.61
Total Non-Current Liabilities+	0	0	172.6K	65.49K	534.47K
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	172.6K	65.49K	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	534.47K
Total Liabilities	40.61K	215.62K	760.87K	1.36M	2.33M
Total Debt+	24K	0	283.22K	210.49K	0
Net Debt	10.65K	-411.86K	-871.68K	-3.12M	-3.98M
Debt / Equity	-	-	0.25x	0.06x	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-680.22x	-192.58x	-2.54x
Total Equity+	-23.59K	450.63K	1.13M	3.83M	6.66M
Equity Growth %	-	20.1%	1.51%	2.38%	0.74%
Book Value per Share	-0.01	0.17	0.42	5.60	292.88
Total Shareholders' Equity	-23.59K	450.63K	1.13M	3.83M	6.66M
Common Stock	848	952	957	1.73K	44
Retained Earnings	-137.37K	-922.11K	-2.72M	-7.02M	-13.27M
Treasury Stock	0	0	0	0	0
Accumulated OCI	-1.22K	202	111	202	-337
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-217.16K	-660.93K	-1.59M	-4.56M	-5.49M
Operating CF Margin %	-	-799.19%	-2.07%	-2.66%	-2.22%
Operating CF Growth %	-	-2.04%	-1.4%	-1.87%	-0.2%
Net Income	-222.91K	-784.74K	-1.8M	-4.3M	-6.25M
Depreciation & Amortization	0	2.76K	6.51K	11.65K	12.95K
Stock-Based Compensation	0	142.35K	171.87K	487.74K	97.17K
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	-1.04K	600	23.58K	68.51K	396.97K
Working Capital Changes	6.79K	-21.91K	12.43K	-823.19K	251.67K
Change in Receivables	-605	-1.35K	-11.55K	-23.22K	-12.97K
Change in Inventory	0	-160.82K	-69.33K	-265.52K	-403.3K
Change in Payables	0	192.09K	65.19K	466.89K	207.5K
Cash from Investing+	0	-32.48K	-32.03K	-11.19K	-610.56K
Capital Expenditures	0	-32.48K	-35.53K	-11.19K	-9.16K
CapEx % of Revenue	-	39.28%	0.05%	0.01%	0%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	3.5K	0	-462.32K
Cash from Financing+	238.28K	1.09M	2.36M	6.74M	6.76M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	238.28K	0	25K	-724.7K	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-217.16K	-693.42K	-1.62M	-4.57M	-5.49M
FCF Margin %	-	-838.47%	-2.12%	-2.67%	-2.22%
FCF Growth %	-	-2.19%	-1.34%	-1.82%	-0.2%
FCF per Share	-0.08	-0.26	-0.60	-6.69	-241.31
FCF Conversion (FCF/Net Income)	0.97x	0.84x	0.88x	1.06x	0.88x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-367.53%	-227.6%	-173.5%	-119.12%
Return on Invested Capital (ROIC)	-	-4559%	-898.95%	-581.25%	-82.69%
Gross Margin	-	-244.01%	58.37%	66.25%	72.84%
Net Margin	-	-94889.84%	-234.94%	-251.17%	-253.14%
Debt / Equity	-	-	0.25x	0.06x	-
Interest Coverage	-	-	-680.22x	-192.58x	-2.54x
FCF Conversion	0.97x	0.84x	0.88x	1.06x	0.88x
Revenue Growth	-	-	92557.44%	123.5%	44.07%

Revenue by Geography

	2023
UNITED STATES	1.71M
UNITED STATES Growth	-
AUSTRIA	234.8K
AUSTRIA Growth	-
CANADA	158.6K
CANADA Growth	-
VIET NAM	70.66K
VIET NAM Growth	-

Frequently Asked Questions

Growth & Financials

PMGC Holdings Inc. (ELAB) reported $-1.5M in revenue for fiscal year 2024.

PMGC Holdings Inc. (ELAB) grew revenue by 44.1% over the past year. This is strong growth.

PMGC Holdings Inc. (ELAB) reported a net loss of $6.7M for fiscal year 2024.

Dividend & Returns

PMGC Holdings Inc. (ELAB) has a return on equity (ROE) of -119.1%. Negative ROE indicates the company is unprofitable.

PMGC Holdings Inc. (ELAB) had negative free cash flow of $6.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener